8-K: Passage Bio Receives Nasdaq Delisting Notice Due to Low Share Price

Passage Bio has been notified by Nasdaq that it no longer meets the minimum bid price requirement for continued listing, triggering a potential delisting process.

Summary

• Passage Bio received a notice from Nasdaq on August 1, 2024, stating that its common stock price has fallen below $1.00 per share for 30 consecutive business days.
• This non-compliance with Nasdaq Listing Rule 5450(a)(1) triggers a potential delisting from the Nasdaq Global Select Market.
• Passage Bio has been granted an initial 180-day compliance period, until January 28, 2025, to regain compliance by having its stock price meet or exceed $1.00 for at least 10 consecutive business days.
• If the company fails to regain compliance by January 28, 2025, it may be eligible for an additional 180-day grace period by transferring its listing to the Nasdaq Capital Market, provided it meets other listing requirements.
• To qualify for the additional grace period, Passage Bio would need to meet the market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, except for the minimum bid price, and provide written notice of its intention to cure the minimum bid price deficiency, potentially through a reverse stock split.
• If the company cannot cure the deficiency or is not eligible for the additional period, Nasdaq will issue a delisting notice, which the company can appeal.
• The company is considering actions to regain compliance but has not made any decisions yet, and there is no guarantee that it will be able to regain compliance.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the uncertainty surrounding the company's ability to regain compliance. The lack of a concrete plan to address the issue further contributes to the negative outlook.

Positives

• The company has been granted an initial 180-day period to regain compliance.
• There is a possibility of an additional 180-day grace period if the company transfers to the Nasdaq Capital Market.
• The company has the right to appeal a delisting determination.

Negatives

• The company's stock price has fallen below the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.
• There is a risk of delisting if the company fails to regain compliance within the given timeframes.
• The company has not yet decided on a specific course of action to regain compliance.

Risks

• The company faces the risk of being delisted from the Nasdaq Global Select Market if it cannot regain compliance with the minimum bid price requirement.
• There is no guarantee that the company will be able to regain compliance, even with the potential for an additional grace period.
• The company's stock price may be negatively impacted by the delisting notice and the uncertainty surrounding its future listing status.

Future Outlook

The company is considering actions to regain compliance with Nasdaq listing requirements, but no decisions have been made, and there is no assurance of success.

Management Comments

• The company is considering actions that it may take in response to this Notice to regain compliance with the continued listing requirements, but no decisions about a response have been made at this time.

Industry Context

Delisting notices are not uncommon for companies experiencing prolonged stock price declines, particularly in the biotech sector where market sentiment can be volatile. This situation highlights the challenges faced by companies in maintaining listing compliance during periods of financial or operational uncertainty.

Comparison to Industry Standards

• Many biotech companies, especially those in the development stage, face challenges in maintaining stock prices above the minimum bid price requirement.
• Companies like Athersys and Ocugen have faced similar delisting notices in the past, highlighting the commonality of this issue in the biotech industry.
• The response to a delisting notice can vary, with some companies successfully regaining compliance through reverse stock splits or other measures, while others are ultimately delisted.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment due to the delisting notice.
• Employees may face uncertainty about the company's future.
• The company's reputation may be negatively impacted.

Next Steps

• The company will consider actions to regain compliance with Nasdaq listing requirements.
• The company may need to implement a reverse stock split to increase its share price.
• The company may need to transfer its listing to the Nasdaq Capital Market if it cannot regain compliance on the Global Select Market.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, stock price, reverse stock split, listing rule, Passage Bio